This presentation contains forward-looking statements, including statements regarding the timing of expected reimbursement and coverage decisions and regulatory approvals for NERLYNX. All statements other than historical facts are forward–looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward–looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in Puma’s Annual Report on Form 10-K for the year ended December 31, 2017 and any subsequent documents Puma files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.
Puma’s Pharmacy and Distributor Network

Specialty Pharmacy Network
- Acaria Health
- Accredo
- CVS
- Onco360
- Diplomat
- Biologics

Specialty Distributor Network
- McKesson
- ASD / Oncology Supply
- Cardinal Health

Hub Services

Patients

Sites of Care
- Academic Hospitals
- Community Hospitals
- Private Practice
- Other (VA, DoD)
Net Product Sales Grew 41% from Q1 to Q2

NERLYNX NET SALES (IN $M)

Q3-2017: $6.1
Q4-2017: $20.1
Q1-2018: $36.0
Q2-2018: $50.8

+ 41%
Active Patients on NERLYNX® by Month

TOTAL ACTIVE COMMERCIAL PATIENTS IN SP AND SD CHANNELS BY MONTH

- Active Patients = Specialty Pharmacy (SP) channel active patients + estimated Specialty Distribution (SD) channel patients
- NOTE: Active Patients are net of discontinued and completed patients which are netted out in month of last shipment

Copyright 2018 Puma Biotechnology
72% of patients receive their first dispense within 15 days of an SP in our network receiving their RX
63% of Targeted Prescribers Reached

*C Call numbers reported for historical quarters may be slightly different from previous statements due to Veeva data updates*
NERLYNX® Inclusion in Clinical Guidelines

Extended Adjuvant Breast Cancer

National Comprehensive Cancer Network®

American Society of Clinical Oncology

St. Gallen Symposium

Breast Cancer Brain Metastases*

National Comprehensive Cancer Network®

*Non-Promotional
Europe and Canada Launch Progress

Puma Europe Operations / Canada Operations

- Supply Chain and Commercial infrastructure being established
- Global Value Dossier amended for EMA indication
- Country specific Health Technology Assessment Dossiers under development

Germany

- Early GBA (Gemeinsamer Bundesausschuss) consultation completed
  - Agreement on endpoint and comparator

France

- Health Authority consultation being scheduled, coverage decision by Q4 2019

United Kingdom

- NICE appraisal starts in Q4 2018, decision expected by Q4 2019
## Rest of World Partnerships – Timelines

<table>
<thead>
<tr>
<th>Region</th>
<th>Partner</th>
<th>Expected Regulatory Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Australia</strong></td>
<td><img src="image" alt="Specialised Therapeutics Logo" /></td>
<td>• 1H 2019</td>
</tr>
<tr>
<td><strong>Israel</strong></td>
<td><img src="image" alt="MEDISON Logo" /></td>
<td>• Mid 2019</td>
</tr>
<tr>
<td><strong>China</strong></td>
<td><img src="image" alt="CANbridge Logo" /></td>
<td>• 2H 2019</td>
</tr>
<tr>
<td><strong>Latin America</strong></td>
<td><img src="image" alt="PINT PHARMA Logo" /></td>
<td>• 2H 2019 – Argentina</td>
</tr>
<tr>
<td><strong>South America</strong></td>
<td></td>
<td>• 2H 2019 – Chile</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1H 2020 – Ecuador</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1H 2020 – Mexico</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 1H 2020 – Peru</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2H 2020 – Brazil</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 2H 2020 – Colombia</td>
</tr>
</tbody>
</table>
Puma Biotechnology
Earnings Call
Commercial Update
August 9, 2018